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Desensitizationa b s t r a c t
Nanoparticles have successfully been employed in immunometric assays that require high sensitivity.
Certain analytes, however, require dynamic ranges (DRs) around a predetermined cut-off value. Here,
we have studied the effects that antibody orientation and addition of free solid-phase and detection
antibodies have on assay sensitivity and DR in traditional sandwich-type immunoassays. D-dimer and
cardiac troponin I (cTnI), both routinely used in critical care testing, were applied as model analytes.
The assays were performed in microtitration wells with preimmobilized solid-phase antibody. Inherently
fluorescent nanoparticles coated with second antibody were used to detect the analyte. The selection of
antibody orientation and addition of free solid-phase or detection antibody, with nanoparticles and cal-
ibrator, desensitized the assays and extended the DR. With D-dimer the upper limit of the DR was
improved from 50 to 10,000 ng/ml, and with cTnI from 25 to 1000 ng/ml. Regression analysis with the
Stago STA Liatest D-dimer assay yielded a slope (95% confidence interval) of 0.09 (0.07–0.11) and a y-
intercept of 7.79 (17.87–2.29) ng/L (n = 65, r = 0.906). Thus it is concluded that Europium(III)-che-
late-doped nanoparticles can also be employed in immunoassays that require wide DRs around a certain
cut-off limit.
 2013 Elsevier Inc. All rights reserved.Time-resolved fluorimetry of lanthanide chelate labels has
established a distinguished role in bioaffinity assays during the
past years [1]. Commercially available polystyrene beads contain-
ing >30,000 europium chelates, in combination with a derivatized
surface, enabling immobilization of large numbers of binder
reagents, have created exceptionally powerful detector modalities
to achieve highly sensitive assays using simple test designs [2,3].
An ultimate illustration of this technology is that a single nanopar-
ticle can be detected from a solution [2]. The wide applicability of
Eu nanoparticles has been demonstrated in numerous bioaffinity
assays for protein- [4], nucleic acid- [5], and virus-based diagnos-
tics [6].
While the Eu-nanoparticle approach has provided ample
evidence for exquisite analytical immunoassay sensitivities, the
aim of this study was to investigate different approaches for the
desensitization and extension of the dynamic range (DR)1 of
Eu-nanoparticle-based assays, while still using a conventional sand-
wich-type test approach. D-dimer and cardiac troponin I (cTnI), both
commonly used critical care analytes, were selected as modelanalytes. Unlike cTnI, D-dimer requires a wide DR around a clinically
predetermined comparatively high cut-off value. Hence, the analyte
calls for test approaches capable of combining simplicity, speed,
specificity, and a wide DR. The functionality of the D-dimer assay
was tested by measuring a panel of patient citrated plasma samples
with the desensitized novel assay and the results were compared to
a commercially available immunoturbidimetric assay.Materials and methods
D-dimer and cTnI calibrators and clinical samples
The D-dimer calibration material was prepared from partially
purified D-dimer from human fibrin digested with human plasmin
(Biokit, Barcelona, Spain), and human cTnI (native, tissue-derived
cTnI–cardiac troponin T–troponin C complex) was purchased from
HyTest (Turku, Finland). The calibrators were diluted in sample
buffer containing 137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L
Na2HPO4, 2 mmol/L KH2PO4, and 10 g/L bovine serum albumin
(BSA) (pH 7.2). Citrated leftover plasma samples (n = 65) were ran-
domly collected at Oulu University Hospital (Oulu, Finland). The
frozen samples were thereafter shipped to the University of Turku
on dry ice and stored frozen at 70 C. Prior to the analysis, the
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Fig.1. The principle of the developed sandwich-type modified one-step nanoparticle-based immunoassay for D-dimer using monoclonal FDP14 as the solid phase and
8D3F(ab0)2 as the detection antibody attached to nanoparticles. The biotinylated monoclonal solid-phase antibody was immobilized into SAv-coated microtitration wells.
Sample (12 ll) was applied simultaneous with europium(III)-chelate doped nanoparticles and free solid-phase or detection antibody (48 ll) to BSA-coated microtitration
wells, and the solution was mixed for a 30-s preincubation. After the preincubation, 50 ll of the solution was moved to the solid-phase surface and the assay was incubated
for 5 min at 23 C. After the incubation, the wells were washed and europium fluorescence was measured in a time-resolved mode (not to scale).
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(1 min, 2000g) to remove any particulate material.
Biotinylation of antibodies and preparation of solid-phase surfaces
A monoclonal antibody that specifically recognizes degraded
forms of human fibrin and fibrinogen but not intact fibrin and
fibrinogen (FDP14) and a monoclonal fragment antigen binding
(F(ab0)2) of antibody that specifically recognizes the D-dimer do-
main contained in the cross-linked degradation products of human
fibrin (8D3) were from Biokit. Monoclonal cTnI-specific antibody
8I7 was purchased from International Point of Care (Toronto, ON,
Canada) and monoclonal antibody 9707 was purchased from Med-
ix Biochemica (Kauniainen, Finland). The solid-phase antibody
FDP14 was biotinylated for 1 h at +23 C, protected from light, in
50 mmol/L Na2CO3/NaHCO3 buffer (pH 9.6) containing 150 mmol/
L NaCl with 10-fold molar excess of EZ-Link NHS-Chromogenic-
Biotin (Thermo Scientific, Rockford, IL, USA). The solid-phase anti-
body 8D3F(ab0)2 was biotinylated for 1 h at +23 C, protected from
light, in 100 mmol/L phosphate buffer (pH 7.2) containing
150 mmol/L NaCl with 5-fold molar excess of EZ-Link NHS-Chro-
mogenic-Biotin. Both biotinylated antibodies were purified with
NAP-10 and PD-10 gel-filtration columns (GE Healthcare, Schenec-
tady, NY, USA) by using 50 mmol/L Tris–HCl (pH 7.75), containing
150 mmol/L NaCl and 0.5 g/L NaN3. The labeling degree for the
FDP14 was 3 and for 8D3F(ab0)2 2 biotins per antibody. The labeled
antibodies were stabilized with 1 g/L BSA (Bioreba, Nyon, Switzer-
land) and stored at +4 C. The cTnI-specific antibodies were labeled
with 10-fold (9707) and 20-fold (8I7) molar excess of biotin isothi-
ocyanate using a procedure described earlier [7].
The assays were performed in streptavidin (SAv)-coated
microtiter wells. Biotinylated solid-phase antibody (120 ng) was
immobilized to SAv-coated wells in 60 ll of assay buffer (Kaivogen
buffer solution red; Kaivogen Oy, Turku, Finland). After 1 hincubation at +23 C and shaking at 900 rpm, the wells were
washed four times with wash solution (Kaivogen wash concen-
trate; Kaivogen Oy) and used immediately in the assay.Conjugation of antibodies to detector nanoparticles
Nanoparticles were purchased from Seradyn (Indianapolis, IN,
USA) and were internally dyed, monodisperse, carboxyl-modified
Fluoro-Max polystyrene, 107-nm particles (carboxyl content
0.157 mEq/g, parking area 56.6 Å2), which produce a long-lifetime
fluorescence equivalent to 30,000 chelated ions per particle [2].
Primary amino groups of FDP14 and 8D3F(ab0)2 were covalently
coupled to activated carboxyl groups of the nanoparticles using a
procedure described previously with some minor modifications
[6]. The nanoparticles (1.5  1012 particles) were suspended in
10 mmol/L phosphate buffer (pH 7.0), and their surfaces were
activated with 0.75 mmol/L N-(3-dimethylaminopropyl)-N0-ethyl-
carbodiimide (Sigma–Aldrich, St. Louis, MO, USA) and 10 mmol/L
N-hydroxysulfosuccinimide sodium salt (Sigma–Aldrich). The con-
centrations of FDP14 and 8D3F(ab0)2 in the coupling reactions were
1.0 and 0.8 mg/ml, respectively, and the reactions contained
100 mmol/L NaCl. The activated particles were mixed either di-
rectly (8D3F(ab0)2) or dropwise (FDP14) with the antibodies. The
coupling reactions were incubated for either 50 min (FDP14) or
2 h (8D3F(ab0)2) at +23 C under vigorous shaking. Final washes
and blocking of the remaining active groups were performed in
Tris-based buffer (10 mmol/L Tris, 0.5 g/L NaN3, pH 8.5), and the
nanoparticle–antibody conjugates were stored in the same buffer
supplemented with 2 g/L BSA at 4 C. Before the first instance of
use, the particles were mixed thoroughly, sonicated, and centri-
fuged lightly (350g, 5 min) to separate noncolloidal aggregates
from the monodisperse suspension. The cTnI-specific conjugates
were prepared as described previously [8].
Fig.2. Dose–response curves for the D-dimer and cTnI immunoassays. The error bars represent the standard deviation measured from three replicate microtitration wells. (A)
The D-dimer assay exploiting 8D3F(ab0)2 as the solid-phase and FDP14 as the detection antibody. (j) 0 lg/ml free FDP14/8D3F(ab0)2, (d) 5 lg/ml free 8D3F(ab0)2, (.) 15 lg/
ml free 8D3F(ab0)2, (}) 5 lg/ml free FDP14, and (s) 15 lg/ml free FDP14. (B) The D-dimer assay exploiting FDP14 as the solid-phase and 8D3F(ab0)2 as the detection antibody.
(j) 0 lg/ml free DP14/8D3F(ab0)2, (N) 5 lg/ml free 8D3F(ab0)2, (d) 15 lg/ml free 8D3F(ab0)2, (h) 1 lg/ml free FDP14, and (}) 5 lg/ml free FDP14. (C) The cTnI assay exploiting
8I7 as the solid-phase and 9707 as the detection antibody. (h) 0 lg/ml free 8I7/9707, (N) 5 lg/ml free 9707, (.) 10 lg/ml free 9707, (d) 25 lg/ml free 9707, and (}) 10 lg/ml
free 8I7. (D) The cTnI assay exploiting 9707 as the solid-phase and 8I7 as the detection antibody. (h) 0 lg/ml free 8I7/9707, (N) 5 lg/ml free 8I7, (.) 10 lg/ml free 8I7, (d)
25 lg/ml free 8I7, and (}) 10 lg/ml free 9707.
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The D-dimer-specific nanoparticle-based immunoassays were
developed by employing FDP14 as the solid phase and 8D3F(ab0)2
as the detection antibody (Fig. 1) or vice versa. The cTnI assays
were developed identical to the D-dimer assays, but employing
8I7 and 9707 antibodies. The immunoassays were performed as
modified one-step sandwich-type formats with preincubation of
the calibrator, free solid-phase or detection antibody, and anti-
body-coated detection nanoparticles prior to presentation to the
specific solid-phase surface. The preincubation step was added to
simulate the usage of simple microfluidic chip processing, in which
sample and detector are first introduced and thereafter transferred
to the solid-phase surface.
First 1.44  109 (1.8  108 for cTnI assays) detection antibody-
coated nanoparticles along with 0–25 lg/ml free solid-phase or
detection antibodies were added in 48 ll of particle buffer (assay
buffer supplemented with 0.1 g/L native mouse IgG, 0.05 g/L dena-
tured mouse IgG; Meridian Life Science, Saco, ME, USA) to wells
that were coated with 5 g/L BSA. The samples or calibrators were
added in 12 ll, and the solution was preincubated for 30 s at+23 C with shaking at 900 rpm. After the preincubation in BSA-
coated wells, 50 ll of the calibrator-particle solution was
transferred to the solid-phase surface. The assay wells were then
incubated for 5 min at +23 C with shaking at 900 rpm. Finally,
the wells were washed thoroughly with wash solution and long
lifetime fluorescence of the bound nanoparticle bioconjugates
was measured directly from the surface of the well in a time-re-
solved mode with a Victor 1420 multilabel counter (PerkinElmer
Life and Analytical Sciences, Wallac Oy, Turku, Finland).
Assay desensitization and evaluation
The extension of D-dimer assay DR was studied by supplement-
ing 0–15 lg/ml free solid-phase or detection antibody into the
particle buffer when 8D3F(ab0)2 was used as the detection anti-
body and FDP14 as the solid-phase antibody. When the two anti-
bodies were in reversed order (FDP14 as the solid-phase and
8D3F(ab0)2 as the detection antibody), 0–15 lg/ml free 8D3F(ab0)2
and 0–5 lg/ml free FDP14 were tested. When cTnI was used as
the analyte, 0 and 10 lg/ml free solid-phase antibody and
0–25 lg/ml free detection antibody were applied. The DRs of the
Table 1
The calculated limit of blank (LoB) and upper limit of dynamic range (DR) of the
various assay configurations tested
LoB (ng/ml) DR (ng/ml)
D-dimer
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that was a linear function of the input calibrator amount. Limit
of blank (LoB) was determined according to Clinical Laboratory
Standards Institute (CLSI) Guideline EP17-A (n = 12), as determined
with the nonparametric option [9].8D3F(ab0)2–FDP14
0 lg/ml free FDP14/8D3F(ab0)2 0.249 650
5 lg/ml free 8D3F(ab0)2 (solid phase) 0.463 650
15 lg/ml free 8D3F(ab0)2 (solid phase) 0.158 6200
5 lg/ml free FDP14 (detection) 2.73 61000
15 lg/ml free FDP14 (detection) 13.6 610,000
FDP14–8D3F(ab0)2
0 lg/ml free FDP14/8D3F(ab0)2 1.17 6500
1 lg/ml free FDP14 (solid phase) 2.75 610,000
5 lg/ml free FDP14 (solid phase) 478 610,000
5 lg/ml free 8D3F(ab0)2 (detection) 0.331 61000
15 lg/ml free 8D3F(ab0)2 (detection) 0.603 63000
Cardiac troponin I
8I7–9707
0 lg/ml free 8I7/9707 0.0100 625
10 lg/ml free 8I7 (solid phase) 1.03 650
5 lg/ml free 9707 (detection) 0.0356 6100
10 lg/ml free 9707 (detection) 0.0808 6250
25 lg/ml free 9707 (detection) 0.0367 61000
9707–8I7
0 lg/ml free 8I7/9707 0.00300 625
10 lg/ml free 9707 (solid phase) 1.06 650Method comparison
The performance parameters of the developed D-dimer immu-
noassay (FDP14 as the solid-phase and 8D3F(ab0)2 as the detection
antibody, with 1 lg/ml free FDP14) were tested (with 15-min
incubation) against a commercially available quantitative immu-
noturbidimetric latex agglutination STA Liatest D-dimer assay
(Diagnostica Stago, Parsippany, NJ, USA) with a Stago STA-R Evolu-
tion device (Diagnostica Stago). The comparison assays were per-
formed at the University Hospital of Oulu according to the
manufacturer’s instructions. The results of the comparison assay
were given as ng/ml fibrinogen equivalent units (FEU), and a D-di-
mer result of P500 ng/ml (FEU) was considered positive. Assay
descriptives and Pearson correlation was calculated with IBM SPSS
Statistics 21 (SPSS, Inc., Chicago, IL, USA). Method comparison was
performed by calculating Deming regression parameters with Ana-
lyze-It software (Analyze-It Software Ltd., Leeds, UK).5 lg/ml free 8I7 (detection) 0.00850 650
10 lg/ml free 8I7 (detection) 0.0154 6100
25 lg/ml free 8I7 (detection) 0.290 61000Results and discussion
The principle of the developed D-dimer immunoassay can be
seen in Fig. 1. The antibodies were tested with FDP14 (8I7, cTnI)
as the solid-phase and 8D3F(ab0)2 (9707, cTnI) as the detection
antibody attached to nanoparticles or vice versa. The assays were
performed as a modified one-step format in which the analyte,
antibody-coated detection particles, and free antibody were prein-
cubated for 30 s in BSA-coated wells and thereafter transferred to a
solid-phase antibody-coated capture surface. The preincubation
step was employed, since the ultimate goal is to use the assay in
a simple microfluidic chip, where the calibrator and detection
nanoparticles are first introduced and later transferred to a solid-
phase surface. Extension of DR was expected, as the free antibody
competes for the binding to the analyte with the solid-phase and
the detection antibodies, respectively.
Typical calibration curves for the developed assays are shown in
Fig. 2A and B for D-dimer and Fig. 2C and D for cTnI. When the
8D3F(ab0)2/FDP14 solid-phase/detection configuration was em-
ployed in the D-dimer assay, addition of 15 lg/ml free solid-phase
antibody (8D3F(ab0)2) widened the upper limit of DR of the assay
4-fold, from 50 to 200 ng/ml (Table 1). Addition of free detection
antibody (FDP14) had a clearly more significant effect on DR: addi-
tion of 15 lg/ml free FDP14 extended the upper limit of DR 200-
fold to 10,000 ng/ml. When antibodies were employed in the re-
verse configuration (FDP14/8D3F(ab0)2), the DR was 6500 ng/ml
without the addition of free antibodies. Addition of free detection
antibody (8D3F(ab0)2) had a moderate effect on the DR; addition
of 15 lg/ml free detection antibody increased the upper limit of
DR 6-fold from 500 to 3000 ng/ml. Addition of 1 or 5 lg/ml free
solid-phase antibody (FDP14) increased the DR 20-fold to
10,000 ng/ml. Thus, regardless of the antibody orientation in the
assay, addition of free FDP14 had clearly better effects on shifting
the assay DR than the addition of free 8D3F(ab0)2. With the
FDP14/8D3F(ab0)2 configuration the amounts of free FDP14
required to shift the DR were significantly smaller than with the
reverse antibody orientation. No high-dose hook was observed in
the assays, and the signals were still increasing at 10,000 ng/ml,
which was the highest D-dimer concentration measured. The low-
est D-dimer concentration tested was 10 ng/ml, although lower
concentrations would have been in the linear range for many ofthe tested assay versions. The widely used clinical cut-off level of
D-dimer is 500 ng/ml (FEU) [10]. For cTnI, both assay configura-
tions reacted very similar to the antibody additions: the addition
of 10 lg/ml free solid-phase antibody increased the upper limit
of DR 2-fold from 25 to 50 ng/ml (Table 1). The addition of
10 lg/ml free solid-phase antibody also resulted in a high-dose
hook: most clearly seen with the 9707/8I7 configuration. The addi-
tion of 25 lg/ml free detection antibody increased the upper limit
of DR 40-fold to 1000 ng/ml with both configurations.
LoBs, determined according to CLSI Guideline EP17-A, can be
seen on Table 1. With the 8D3F(ab0)2/FDP14 configuration the
LoB was <1 ng/ml. Employing the second antibody orientation
(FDP14/8D3F(ab0)2) resulted in an approximately fivefold
(1.17 ng/ml) less sensitive assay, but produced a wider linear range
and shifted the range toward higher concentrations (0.249–50 ng/
ml vs 1.17–500 ng/ml). For cTnI and the 8I7/9707 configuration,
the LoB was 0.0100 ng/ml. Employing the reverse antibody orien-
tation (9707/8I7) resulted in a threefold less sensitive assay
(0.300 ng/ml). With the 8I7/9707 configuration, the addition of
free detection antibody (9707) did not affect the LoB as remarkably
as with the 9707/8I7 configuration and the addition of free detec-
tion antibody (8I7). The addition of 25 lg/ml free detection anti-
body with the 9707/8I7 configuration resulted in an eightfold
more sensitive assay than with the opposite configuration
(0.0367 vs 0.290). As the amount of the free antibody increased,
so did the LoB in the majority of assay versions. As the amount
of free antibody was increased, fewer antigens were able to bind
both solid-phase and detection antibodies, thus resulting in assay
desensitization. Consequently the antibody orientation itself in
two-site immunoassays may have significant effects on the assay
sensitivity and positioning of the DR.
Extending the assay DR in immunoassays is traditionally ap-
proached by trying to achieve an assay that is as sensitive as pos-
sible and allows small sample volumes to be used [11]. The use of
the highest possible excesses of functionally active binders serves
the purpose of providing an opportunity for high DRs in combina-
tion with light-producing reporter techniques [12]. The use of
excess solid-phase and detector reagents also serves to shorten
Fig.3. Method comparison. (A) Correlation between the developed D-dimer assay and STA Liatest D-dimer assay. (n = 65, r = 0.906) (B) Bland–Altman analysis of agreement
between the two methods. Solid horizontal line represents the mean difference and dotted lines the 95% limits of agreement.
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sensitivities assuming that the nonspecific binding can be
controlled [13]. Using multiple antibodies with differing affinities
simultaneously has also been used to obtain extended DRs: an ap-
proach that requires multiple additional steps [14]. Novel ways to
enhance the DR in protein detection assays include the use of spe-
cifically labeled fluorescence immunosensors [15] and the use of
plasmonic structures and molecular spacers that enhance the DR
up to 8 orders of magnitude in comparison to traditional assays
[16].
The applicability of the developed D-dimer assay to measure
plasma D-dimer was investigated by measuring 65 citrated plasma
samples left over from hospital routine analysis. Using an assay
time (5 min) in which the signal is rapidly developing increases
the possibility of between-run imprecision. Thus a 15-min incuba-
tion time was selected when analyzing the plasma samples. The
median concentration of D-dimer (lower and upper quartiles)
was 1700 ng/ml (575 and 4485 ng/ml, FEU) when measured with
the immunoturbidimetric comparison assay, whereas the median
D-dimer concentration measured with the developed nanoparti-
cle-based assay was 111 ng/ml (36.5 and 354 ng/ml). The
regression analysis yielded a slope (95% confidence intervals) of
0.09 (0.07–0.11) and a y-intercept of 7.79 (17.87–2.29) ng/L.
The Spearman correlation coefficient was 0.906 (P < 0.0001). The
mean relative difference between the two methods was 170% with
the 95% limits of agreement ranging from 209 to 131% (Fig. 3).Conclusions
Desensitization and extension of DRs for nanoparticle-based as-
says for D-dimer and cTnI were performed by selecting the correct
antibody configuration and addition of free solid-phase or detec-
tion antibodies. For cTnI, the addition of free solid-phase antibody
had little effect on assay LoB and DR. With the addition of free
detection antibody, an extension of the upper limit of DR by 40-
fold was achieved. For D-dimer, the selection of correct antibody
configuration (FDP14/8D3F(ab0)2) and addition of 1 lg/ml free so-
lid-phase antibody was enough to show an extension of the upper
limit of DR by 200-fold. Hence, europium(III)-chelate doped nano-
particles can be exploited both in immunoassays requiring highsensitivities and in immunoassays that require wide DR around a
specific, nondemanding analyte concentration.
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